Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
Summary
To evaluate the efficacy and safety of dalpiciclib in patients with HR-positive/HER2-positive advanced breast cancer.
Official title: Efficacy and Safety of Dalpiciclib in HR+/HER2- Advanced Breast Cancer: a Real-world Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
103
Start Date
2024-05-03
Completion Date
2028-12
Last Updated
2026-02-03
Healthy Volunteers
No
Conditions
Interventions
DRUG
dalpiciclib
dalpiciclib oral day 1-21, every 28 days
Locations (1)
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Shanghai, China